Press Release

To, Date: 01st July, 2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Subject: Press Release- Disclosure under Reg. 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled: Sai Parenterals' Australian Subsidiary, Noumed Pharmaceuticals, Renews its Exclusive OTC Supply Agreement with Australia's Leading Pharmacy Networks in a Landmark 7½- Year Deal Valued at Australian Dollars (AUD) 202 Millions (Equivalent to INR 1300 crores; 1AUD = INR 64.5). This is for the information and records of the Exchanges, please. Thanking you, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) Encl: As above July 1, 2026 Media Release Sai Parenterals' Australian Subsidiary, Noumed Pharmaceuticals, Renews its Exclusive OTC Supply Agreement with Australia's Leading Pharmacy Networks in a Landmark 7½-Year Deal Valued at Australian Dollars (AUD) 202 Millions (Equivalent to INR 1300 crores; 1AUD = INR 64.5) Renewal reaffirms a multi-year partnership built on consistent delivery, regulatory trust and sustained growth Hyderabad, India | 1st July 2026 Sai Parenterals Limited is pleased to announce that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has successfully renewed its long-term exclusive OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains with an expanded product portfolio, a longer agreement tenure, and a significantly higher agreement value - reflecting a trusted customer relationship. The renewed agreement is valued at AUD 202 Million (approximately INR 1300 crores, at 1 AUD = INR 64.5) for the term - translating to about AUD 27 Million per annum - to be executed over an extended term of 7½ years — with a further 3-year extension option upon mutual consent. The agreement is also structured for continuous growth: it targets the addition of 12 new products every year, steadily increasing the contract's value and scope every year over its life. Effective 1st July 2026, the renewal cements Noumed's position as a preferred, trusted strategic supply partner to Australia's largest pharmacy networks, and materially strengthens Sai Parenterals' international business footprint. Key Highlights ● Exclusive supplier of a comprehensive and growing portfolio of OTC pharmaceutical products across Australia ● Continued supply to leading pharmacy retail brands, reflecting sustained customer trust & confidence ● Noumed continues to manage manufacturing, product sourcing, regulatory compliance, TGA registrations, warehousing, quality assurance and nationwide distribution — the full value chain entrusted to a single, reliable partner ● Built-in new product development pipeline, ensuring the OTC portfolio — and the agreement's value — keeps expanding over the contract period ● A long-tenure agreement with a built-in extension option, offering exceptional revenue certainty and long-term business stability rarely seen in this segment. Strategic Benefits The renewed agreement delivers substantial, multi-layered value: ● Locks in predictable, recurring revenues across the 7½ years (extendable to over a decade) horizon ● Further cements Noumed's presence in the Australian OTC market ● Expands Sai Parenterals' international pharmaceutical business ● Enhances manufacturing scale and operating leverage ● Supports the continuous launch of new OTC products under leading Australian pharmacy brands ● Deepens an already strong relationship with Australia's largest pharmacy retail groups — a relationship now entering its next chapter after years of proven, consistent execution ● Stands out as a trust & confidence in Noumed's regulatory, quality and supply chain capabilities from one of the most discerning and tightly regulated markets in the world As a subsidiary of Sai Parenterals Limited, Noumed's renewed agreement creates substantial, compounding value for the parent company through: ● Improved utilization of regulatory and manufacturing infrastructure ● Increased global presence in regulated pharmaceutical markets ● Enhanced credibility as a preferred, trusted international pharmaceutical partner ● Stronger, longer-duration earnings visibility from recurring OTC business ● A platform for future expansion into additional regulated international markets Mr. Anil Kumar Karusala, Managing Director, Sai Parenterals Limited, said: "The renewal of this exclusive agreement reflects the confidence that Australia's leading pharmacy groups continue to place in our subsidiary, Noumed Pharmaceuticals. It also gives us a leap pad to our future expansion into the other highly regulated markets. We are confident this agreement will continue to generate sustainable, predictable revenues, support future product launches, and create long-term value for Sai Parenterals and its stakeholders. Our company and team will continue to strive to build upon this significant milestone." Mr. Mark Thulborne, CEO, Noumed Pharmaceuticals Pty Ltd, said: “The long tenure of this agreement signifies our capability to build lasting customer relationships, create certainty of forecasted revenues, and — above all — our customers' trust in our ability to deliver quality products on time. This partnership has grown meaningfully over the past few years, and this renewal, for a much longer period, further strengthens our presence in one of the world's most regulated pharmaceutical markets as a reliable partner for a complete value chain.” About Sai Parenterals Established in 2001, Sai Parenteral’s Limited is a global IP-led pharmaceutical formulations company with operations in India and Australia. The Company operates manufacturing facilities in India for injectables and oral dosage forms and has an upcoming facility in Australia for oral dosage forms. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to customers in India, regulated and semi-regulated markets. DISCLAIMER Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sai Parenteral's Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. For any further information, please contact: Mr. Anil Kumar Chief Financial Officer Email: ir@saiparenterals.com For updates and specific queries, please visit https://www.saiparenterals.com/